JCI vs OKUR
JCI: Johnson Controls is a global industrial technology leader delivering integrated, AI-enabled solutions that optimize the energy efficiency, safety, and performance of mission-critical building environments. OKUR: OnKure Therapeutics is a clinical-stage biopharmaceutical company developing next-generation precision small molecule inhibitors to target PI3Kα-driven cancers and vascular anomalies.
Side-by-side fundamentals
| Metric | JCI | OKUR | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $149.03 | $2.62 | |
| Market cap | $90.3B | $106M | |
| P/E as of 2026-10-30 | 26.19 | n/a | |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | 0.82 | n/a | |
| Net margin FY2025, SEC XBRL | +13.9% | n/a | |
| Gross margin FY2025, SEC XBRL | +36.4% | n/a | |
| ROE FY2025, SEC XBRL | +25.5% | -105.9% | JCI higher |
| ROA FY2025, SEC XBRL | +8.7% | -95.8% | JCI higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-06-30 | 0.70 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +4.6% | n/a | |
| Dividend yield as of 2026-09-02 | 1.07% | n/a | |
| Dividend streak (yrs) SEC XBRL | 9 | 0 | JCI higher |
| Beta as of 2026-09-02 | 1.15 | 0.98 | |
| 1-year return as of 2026-10-30 close | +30.5% | -21.8% | JCI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.